The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.
about
Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsThe mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transportA phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemiaHigh efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Small molecule Mcl-1 inhibitors for the treatment of cancer.Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.Venetoclax for the treatment of chronic lymphocytic leukemia.BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
P2860
Q26751444-18997B60-96B1-40DF-835F-5646693DA69DQ35458865-B0244843-A208-43E8-80E3-22870FBCF664Q36276017-599A09C4-0C7A-4C4F-863B-11B966A24770Q37317447-3C24FEC7-F140-49CD-847E-7DEF063F059EQ38244767-D0A07E74-E34E-4CC8-B7EB-5DD95A4C9F3DQ39038037-3C964165-7440-4F5A-8E72-11C2E6C721C2Q39040977-CF51AEDC-E77C-48B1-A087-FD6E8FBBD267Q39177442-4CC8D511-3E2B-4702-AD7B-DFA6FF14AADFQ46633482-EBCF9253-0139-40E9-B9CE-271646392403Q46932352-4BF549CA-BD2E-4C67-805D-D1FD3ECAC97CQ47875923-88623D52-515F-497D-98A7-3F1E4C9D7E30Q51013700-755AFEA9-1197-47A3-B427-2618302351A2Q51280033-F8F7AB6D-5FDC-41F5-B9D7-A6FF150DB053Q53682262-30E9299A-439D-41D9-BF83-4E6B87B2EA65
P2860
The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
The role of lymphatic transpor ...... n family inhibitors navitoclax
@nl
type
label
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
The role of lymphatic transpor ...... n family inhibitors navitoclax
@nl
prefLabel
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
The role of lymphatic transpor ...... n family inhibitors navitoclax
@nl
P2093
P356
P1476
The role of lymphatic transpor ...... itoclax (ABT-263) and ABT-199.
@en
P2093
Andrew J Souers
Chunqiang Zhu
Edna F Choo
Gary Jenkins
Jason Boggs
Joseph W Lubach
Nathaniel D Catron
Richard Voorman
P304
P356
10.1124/DMD.113.055053
P577
2013-11-08T00:00:00Z